Compare Palantir Technologies Inc (PLTR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Viatris Inc — how do they compare? Palantir Technologies Inc trades at $199.01 (market cap $466.48B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Palantir Technologies Inc is far larger — about 23.2× Viatris Inc's market cap, and Viatris Inc pays a 2.74% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and Viatris Inc for 57 Days on average.
| PLTR | VTRS | |
|---|---|---|
Market Cap | $466.48B | $20.12B |
Volume | 15,675,589 | 7,543,511 |
Sector | Technology | Health |
52-Week High | $207.18 | $18.27 |
52-Week Low | $107.27 | $9.74 |
Typical Hold Time | 78 Days | 57 Days |
Enterprise Value | $457.28B | $32.24B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $198.78, up 3.48% with strong bullish technical signals and consecutive earnings beats. The stock shows robust revenue growth from $1.9B in 2022 to $4.48B in 2025, with net income turning positive to $1.63B. Recent partnership with Armada for sovereign AI infrastructure and positive analyst coverage support momentum, though valuation ratios remain elevated.
Outlook remains positive with accelerating AI adoption and strong fundamentals, but high P/E of 165.91 and P/S of 81.08 present valuation risks. Analyst consensus price target of $185.58 suggests potential downside, while growth trajectory and institutional bullish sentiment offer upside potential amid competitive and execution risks.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
